Posted by Michael Wonder on 22 Jun 2023
Upadacitinib monohydrate for the treatment of patients with previously treated moderately to severely active Crohn’s disease
21 June 2023 - NICE has published final evidence-based recommendations on the use of upadacitinib monohydrate (Rinvoq) for the treatment of adults with previously treated moderately to severely active Crohn’s disease.
Upadacitinib monohydrate is recommended as an option for the treatment of adults with moderately to severely active Crohn's disease only if the disease has not responded well enough or lost response to a previous biological treatment or a previous biological treatment was not tolerated or the use of a tumour necrosis factor (TNF) alfa antagonist is contra-indicated.
